Last updated on July 2019

Exploring the safety and tolerability of conversion to dose-titrated Oral Siponimod in patients with advancing forms of relapsing multiple sclerosis: A 6-month open label, multi-center Phase IIIb study (EXCHANGE) Protocol Number: CBAF312AUS02

Brief description of study

The purpose of the study is to see how safe it is and how well you tolerate changing the MS medicine you are taking currently for your MS to siponimod (an investigational drug for MS). The results of this study will help doctors decide if and when to switch patients from other MS medicines (also known as disease modifying therapies or DMTs) to siponimod.


Clinical Study Identifier: TX220307

Find a site near you

Start Over

Baptist Health Lexington Clinical Research Center

1740 Nicholasville Road Lexington, KY United States
  Connect »